Medium term (core business, net of currency effects): Revenues growth in the mid single-digit percentage range
Adjusted EBITDA margin between 22% and 23%
Adjusted earnings per share in euros to increase by at least 10% Revenues growth in the high single-digit percentage range
Adjusted EBITDA margin of around 23%
Adjusted earnings per share in euros to increase by at least 10% per year
Forecast Adjusted EBITDA stood at EUR 54m in the first quarter of 2021. In the core business, adjusted EBITDA rose organically by 7.0% year on year to EUR 57m. The adjusted EBITDA margin in the core business amounted to 19.0%. The adjusted net income was EUR 18m, resulting in adjusted earnings per share of EUR 0.57 with an increase of organically 29.3% (32.6 % as reported) compared to the same quarter in the prior year.
Outlook for the financial year 2021 (core business, currency-adjusted): The Company continued to expand its production capacities for manufacturing injection vials for Covid-19 vaccines in the first quarter of 2021. By doing so, the Company is reaffirming its responsibility and making an important contribution to combating the pandemic by supplying glass vials to be filled with vaccines.
Contact: Jens KürtenGroup Senior Director Communication & MarketingPhone +49 211 6181-250 Telefax +49 211 6181-241 SOURCE Gerresheimer AG For further information: http://www.presseportal.de/nr/9072/dokument?langid=2
https://www.gerresheimer.com/en/company/investor-relations/reports The Quarterly Statement for the first quarter of 2021 is available here:
The News Highlights
- Gerresheimer with positive start for the financial year 2021
- Check the latest News news updates and information about business, finance and more.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week